GC Biopharma Corp.

KOSE:A006280 Stock Report

Market Cap: ₩1.9t

GC Biopharma Future Growth

Future criteria checks 4/6

GC Biopharma is forecast to grow earnings and revenue by 96.6% and 9.1% per annum respectively. EPS is expected to grow by 96.9% per annum. Return on equity is forecast to be 4.9% in 3 years.

Key information

96.6%

Earnings growth rate

96.9%

EPS growth rate

Biotechs earnings growth82.6%
Revenue growth rate9.1%
Future return on equity4.9%
Analyst coverage

Good

Last updated13 Dec 2024

Recent future growth updates

Recent updates

Benign Growth For GC Biopharma Corp. (KRX:006280) Underpins Stock's 25% Plummet

Nov 19
Benign Growth For GC Biopharma Corp. (KRX:006280) Underpins Stock's 25% Plummet

Does This Valuation Of GC Biopharma Corp. (KRX:006280) Imply Investors Are Overpaying?

Nov 07
Does This Valuation Of GC Biopharma Corp. (KRX:006280) Imply Investors Are Overpaying?

Is GC Biopharma (KRX:006280) A Risky Investment?

Oct 17
Is GC Biopharma (KRX:006280) A Risky Investment?

There's No Escaping GC Biopharma Corp.'s (KRX:006280) Muted Revenues

Aug 02
There's No Escaping GC Biopharma Corp.'s (KRX:006280) Muted Revenues

A Look At The Fair Value Of GC Biopharma Corp. (KRX:006280)

Jul 12
A Look At The Fair Value Of GC Biopharma Corp. (KRX:006280)

Is GC Biopharma (KRX:006280) A Risky Investment?

May 25
Is GC Biopharma (KRX:006280) A Risky Investment?

GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry

Mar 08
GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry

We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt

May 02
We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt

Are Green Cross Corporation's (KRX:006280) Mixed Financials Driving The Negative Sentiment?

Mar 10
Are Green Cross Corporation's (KRX:006280) Mixed Financials Driving The Negative Sentiment?

Shareholders Are Thrilled That The Green Cross (KRX:006280) Share Price Increased 268%

Feb 18
Shareholders Are Thrilled That The Green Cross (KRX:006280) Share Price Increased 268%

Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet

Jan 31
Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet

Calculating The Intrinsic Value Of Green Cross Corporation (KRX:006280)

Jan 14
Calculating The Intrinsic Value Of Green Cross Corporation (KRX:006280)

What You Need To Know About Green Cross Corporation's (KRX:006280) Investor Composition

Dec 27
What You Need To Know About Green Cross Corporation's (KRX:006280) Investor Composition

Green Cross Corporation's (KRX:006280) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Dec 09
Green Cross Corporation's (KRX:006280) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Does Green Cross's (KRX:006280) Statutory Profit Adequately Reflect Its Underlying Profit?

Nov 21
Does Green Cross's (KRX:006280) Statutory Profit Adequately Reflect Its Underlying Profit?

Earnings and Revenue Growth Forecasts

KOSE:A006280 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20262,022,97261,83344,67578,1837
12/31/20251,872,53540,96734,30079,4337
12/31/20241,710,37712,700-82,4259,7007
9/30/20241,643,983-18,855-73,867-1,541N/A
6/30/20241,618,467-38,195-139,830-52,998N/A
3/31/20241,633,972-29,491-129,119-32,186N/A
12/31/20231,626,644-26,632-130,474-5,473N/A
9/30/20231,633,1721,858-126,608-4,056N/A
6/30/20231,653,48925,441-71,63949,959N/A
3/31/20231,643,85236,611-49,94967,601N/A
12/31/20221,711,31365,45324,464119,154N/A
9/30/20221,702,128108,54112,484115,958N/A
6/30/20221,708,169124,73716,869120,190N/A
3/31/20221,672,535114,84044,668153,978N/A
12/31/20211,537,826123,2122,515125,979N/A
9/30/20211,552,27186,257-24,13281,764N/A
6/30/20211,506,14393,472-25,44976,551N/A
3/31/20211,478,56699,854-47,06350,242N/A
12/31/20201,504,11580,886-65,24735,974N/A
9/30/20201,438,54044,131-90,02719,423N/A
6/30/20201,385,4657,169-114,88318,617N/A
3/31/20201,381,597-8,068-112,05633,761N/A
12/31/20191,357,1171,341-106,13240,291N/A
9/30/20191,352,62521,663-83,77551,994N/A
6/30/20191,338,42014,322-60,75749,220N/A
3/31/20191,324,10623,943-73,86413,184N/A
12/31/20181,334,87834,429-50,25714,410N/A
9/30/20181,314,52732,485-50,3573,751N/A
6/30/20181,318,28542,928N/A-10,559N/A
3/31/20181,306,60664,339N/A-2,504N/A
12/31/20171,287,91653,247N/A57,879N/A
9/30/20171,282,59376,100N/A62,699N/A
6/30/20171,254,11371,435N/A94,298N/A
3/31/20171,227,48562,300N/A90,021N/A
12/31/20161,197,90462,970N/A-1,742N/A
9/30/20161,146,95840,707N/A37,325N/A
6/30/20161,114,39475,617N/A-2,588N/A
3/31/20161,079,27487,817N/A19,702N/A
12/31/20151,047,81294,967N/A45,244N/A
9/30/20151,035,74896,613N/A14,718N/A
6/30/20151,023,13384,250N/A27,796N/A
3/31/2015990,42068,220N/A44,867N/A
12/31/2014975,32783,945N/A56,763N/A
9/30/2014959,76486,914N/A40,360N/A
6/30/2014937,73575,576N/A39,249N/A
3/31/2014908,45679,108N/A4,286N/A
12/31/2013888,16870,066N/A29,689N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A006280 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: A006280 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: A006280 is expected to become profitable in the next 3 years.

Revenue vs Market: A006280's revenue (9.1% per year) is forecast to grow faster than the KR market (8.9% per year).

High Growth Revenue: A006280's revenue (9.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A006280's Return on Equity is forecast to be low in 3 years time (4.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 14:07
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

GC Biopharma Corp. is covered by 27 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
In Pil KimCape Investment & Securities Co., Ltd.
David LeeCLSA
Sunghwan KimCredit Suisse